Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Natalizumab

Malignancies, hepatotoxicities and progressive multifocal leukoencephalopathy: 10 case reports

    • 7 Accesses

    This is a preview of subscription content, log in to check access.

    Reference

    1. Foley J, et al. The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis. Multiple Sclerosis and Related Disorders 39: Apr 2020. Available from: URL: http://doi.org/10.1016/j.msard.2019.101863

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Natalizumab. Reactions Weekly 1790, 170 (2020). https://doi.org/10.1007/s40278-020-74788-4

    Download citation